Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Catalano

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|December 26, 2022
Editorial: Microbiota and metabolites in cancer immunotherapyGiandomenico Roviello, Martina Catalano
Expert Opinion on Therapeutic Targets|August 7, 2025
Serum sodium and cancer: an underrated prognostic and predictive biomarker?Giandomenico Roviello, Martina Catalano
Immunotherapy|August 4, 2022
The latest developments in biomarkers predicting response to immunotherapyGiandomenico Roviello, Melissa Bersanelli, Martina Catalano
Cancer|October 9, 2025
From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancerGiandomenico Roviello, Martina Catalano, Lorenzo Antonuzzo
European Urology|May 14, 2024
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerMartina Catalano, Matteo Santoni, Giandomenico Roviello
Future Oncology (London, England)|July 4, 2023
Tumor microenvironment in renal cell carcinoma: what is the current impact?Martina Catalano, Gabriella Nesi, Giandomenico Roviello
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|January 12, 2023
Immune combinations and complete response: a new hope for metastatic renal cell carcinomaMartina Catalano, Gabriella Nesi, Giandomenico Roviello
Frontiers in Immunology|May 10, 2024
Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancerGiandomenico Roviello, Ismaela Anna Vascotto, Martina Catalano
Clinical Medicine Insights. Oncology|March 3, 2025
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial CancerAdriana Guarino, Matteo Santoni, Martina Catalano, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 2, 2021
Second line of treatment for HER2-positive gastric cancer: an evolving issueGiandomenico Roviello, Martina Catalano, Alberto D'Angelo, et al.
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|December 26, 2022
Editorial: Microbiota and metabolites in cancer immunotherapyGiandomenico Roviello, Martina Catalano
Expert Opinion on Therapeutic Targets|August 7, 2025
Serum sodium and cancer: an underrated prognostic and predictive biomarker?Giandomenico Roviello, Martina Catalano
Immunotherapy|August 4, 2022
The latest developments in biomarkers predicting response to immunotherapyGiandomenico Roviello, Melissa Bersanelli, Martina Catalano
Cancer|October 9, 2025
From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancerGiandomenico Roviello, Martina Catalano, Lorenzo Antonuzzo
European Urology|May 14, 2024
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerMartina Catalano, Matteo Santoni, Giandomenico Roviello
Future Oncology (London, England)|July 4, 2023
Tumor microenvironment in renal cell carcinoma: what is the current impact?Martina Catalano, Gabriella Nesi, Giandomenico Roviello
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|January 12, 2023
Immune combinations and complete response: a new hope for metastatic renal cell carcinomaMartina Catalano, Gabriella Nesi, Giandomenico Roviello
Frontiers in Immunology|May 10, 2024
Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancerGiandomenico Roviello, Ismaela Anna Vascotto, Martina Catalano
Clinical Medicine Insights. Oncology|March 3, 2025
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial CancerAdriana Guarino, Matteo Santoni, Martina Catalano, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 2, 2021
Second line of treatment for HER2-positive gastric cancer: an evolving issueGiandomenico Roviello, Martina Catalano, Alberto D'Angelo, et al.
Pageof 11